

# May 2020 PDL/DUR Board Meeting Minutes

**Date:** May 20, 2020

**Members Present:** Anglim, Blank, King, McGrane, Caldwell, Nauts, Putsch, Miller, Stone, Brown, Maxwell, Jost

**Members Absent:** None

**Others Present:** Sexauer, Feist, Peterson, from DPHHS Medicaid; Novak from Magellan; Barnhill, Sather, Doppler, Woodmansey, Artis, Opitz from Mountain-Pacific; and representatives of drug manufacturers and the public.

**Public Comment:**

The public had an opportunity to address the committee regarding non-agenda items and make other social comments. There were no comments.

**Meeting Minute Review:**

Meeting minutes from April were approved as written. Clarification was made on the leukotriene modifier class after review of additional research information. The board recommended to continue with the same decision as 2019 (Must have montelukast, may add zafirlukast).

**Department Update:**

Dani Feist from the Department thanked all meeting participants for being flexible and accommodating during this unprecedented time of virtual meetings.

**PREFERRED DRUG LIST MEETING**

Results of the Board review of Group 3 (Red category):

CLASS	DRUG NAME	2020 RECOMMENDATIONS	Grandfather
ANTICONVULSANTS	ND-Nayzilam <sup>®</sup> , Valtoco <sup>®</sup> NI- Keppra <sup>®</sup> /Keppra <sup>®</sup> XR, Sabril <sup>®</sup>	<u>Carbamazepine Derivatives</u> -Must have carbamazepine chewable, oral tablets and suspension, a long-acting carbamazepine, and oxcarbazepine immediate release. May add others. <u>First Generation</u> -Must have phenobarbital, phenytoin, mephobarbital, primidone, phenytoin 30mg and 50mg, divalproex IR and ER, ethosuximide capsules and suspension, valproic acid caps and suspension. Do not add felbamate. <u>Second Generation and Others</u> - Must have a rescue	No

CLASS	DRUG NAME	2020 RECOMMENDATIONS	Grandfather
ANTICONVULSANTS (cont.)		product ( <i>with corresponding PA criteria to allow for appropriate access</i> ), gabapentin, lamotrigine, levetiracetam, pregabalin, topiramate IR, zonisamide, and lamotrigine starter pack. May add others.	No
ANTIDEPRESSANTS, OTHER	NI-Fetzima®	Must have bupropion XL, trazodone, mirtazapine, venlafaxine ER. May add others. <i>Trial of 2 different preferred agents required.</i>	Yes
ANTIMIGRAINE AGENTS	ND-Nurtec™ ODT, Reyvow™, Ubrelyvy™, Tosymra™ NI-Emgality®	Must have 1 nasal formulation, 1 injection, and 1 short acting agent (short-acting agents have class effect). May add others.	No
ANTIPARKINSON'S AGENTS NON-ERGOT DOPAMINE RECEPTOR AGONISTS	ND-Nourianz™ Category Expansion	Must have a dopamine agonist, a COMT inhibitor, a MAO-B inhibitor, trihexyphenidyl, benztropine, amantadine, IR carbidopa/levodopa, CR carbidopa/levodopa. May add others.	No
ANTIPSYCHOTICS, ATYPICAL	ND-Caplyta™, Secuado® NI-Vraylar®	Must have aripiprazole, risperidone, quetiapine, olanzapine, ziprasidone, lurasidone and clozapine. May add others. Continue clinical criteria. <i>Develop PA criteria for Caplyta™ and Secuado®.</i>	Yes
GLUCAGON AGENTS	New Category	Therapeutic alternatives	No
MULTIPLE SCLEROSIS AGENTS	ND-Vumerity™	Must have glatiramer and one interferon agent. May add others (excluding physician administered).	Yes

The Board reviewed the blue category in advance of the meeting. Kathy from Magellan reported on new generics and discontinued items in this category. This category of drugs has no new clinically significant information since last review. Board recommendations for Group 2 (Blue category) from 2019 were retained. They are as follows:

CLASS	2020 RECOMMENDATIONS	Grandfather
ANALGESICS, NARCOTIC LONG ACTING	Must have one-long acting formulation of morphine or oxycodone; Must have buprenorphine transdermal formulation. May add others. Continue clinical criteria.	Yes
ALZHEIMER'S AGENTS	Must have donepezil. May add others. Continue PA criteria on memantine products.	Yes
ANTIDEPRESSANTS, SSRIS	Class effect. Must have a diagnosis of VMS associated with menopause for Brisdelle®. <i>Trial of 2 different preferred agents required.</i>	Yes
ANTIHYPERTENSIVES, SYMPATHOLYTICS	Therapeutic alternatives. Must have a clonidine product and a guanfacine product. May add others.	No
MOVEMENT DISORDERS	May add with PA criteria.	No

CLASS	2020 RECOMMENDATIONS	Grandfather
NEUROPATHIC PAIN	Must have duloxetine and gabapentin. May add others. Continue existing specific PA criteria.	Yes
NSAIDS	Class effect. Must have one oral and one topical agent.	No
OPHTHALMIC ALLERGIC CONJUNCTIVITIS	<u>Antihistamines</u> - Class effect. <u>Mast Cell Stabilizers</u> - Class effect.	No
OPHTHALMIC ANTIBIOTICS	Class effect.	No
OPHTHALMIC ANTIBIOTIC-STERIOD COMBINATIONS	Class effect.	No
OPHTHALMICS, ANTI-INFLAMMATORIES	<u>NSAIDS</u> - Class effect. <u>Steroids</u> - Therapeutic Alternatives.	No
OPHTHALMICS, ANTI-INFLAMMATORY/IMMUNOMODULATOR	Therapeutic Alternatives. May add with PA criteria for appropriate use.	No
OPHTHALMIC GLAUCOMA AGENTS	<u>OPHTHALMIC ALPHA 2 ADRENERGIC AGENTS</u> - Must have brimonidine due to increased efficacy. May add others. <u>OPHTHALMIC BETA BLOCKERS</u> - Class effect. <u>OPHTHALMIC CARBONIC ANHYDRASE INHIBITORS/RHO KINASE INHIBITORS</u> - Must have one single agent. May add others. <u>OPHTHALMIC PROSTAGLANDINS</u> - Class effect.	No
OTIC ANTIBIOTICS & COMBOS	Class effect.	No
OTIC ANTI-INFECTIVES & ANESTHETICS	Therapeutic alternatives.	No
OTICS, ANTI-INFLAMMATORY	May add.	No
SEDATIVE HYPNOTICS	Therapeutic alternatives. <u>Benzodiazepines</u> - Must have temazepam. Do not add others. <u>BZ-1 selective agents</u> - Must have 1 BZ-1 selective agent May add others. Do not add ramelteon. Continue Belsomra® clinical criteria.	No
SKELETAL MUSCLE RELAXANTS	Must have baclofen and cyclobenzaprine. Other agents are therapeutic alternatives.	No
STIMULANTS & RELATED AGENTS	<u>Non-Stimulant ADHD agents</u> - Must have atomoxetine. May add other nonstimulants. Continue criteria on clonidine ER and only one preferred agent trial is required.  <u>Stimulants</u> -Trial of 2 preferred agents required. Must have one long acting agent and one short-acting agent each of a methylphenidate-like product and an amphetamine-like product. May add others.	Non-Stimulants-No  Stimulants-Yes

CLASS	2020 RECOMMENDATIONS	Grandfather
SUBSTANCE USE DISORDER TREATMENTS	<u>Opioid Use Disorder Treatments</u> - Therapeutic alternatives. Must have buprenorphine/naloxone film. Do not add buprenorphine monotherapy tablet or buprenorphine/naloxone tablet. <u>Opioid Reversal</u> - Must have injection and nasal naloxone.	No

Two green categories were not reviewed as all chemical entities are preferred at this time.

Class
IDIOPATHIC PULMONARY FIBROSIS
UTERINE DISORDER TREATMENTS

Tony King will be sending out a poll to the DUR Board at a future date to finalize Fall DUR meeting dates. Meeting adjourned at 3:16 PM.